BMC Medical Research Methodology

Table 3 Scenarios 7-13 in the simulation study. Daily doses with dose limiting toxicities in the targeted toxicity interval (0.20 - 0.40) are in boldface

From: Phase I dose-escalation oncology trials with sequential multiple schedules

		Doses with Schedule S₁						Doses with Schedule S₂
Scenario	Schedule	2.5	5	7.5	10	12.5	15	2.5	5	7.5	10	12.5	15
7	S₁	0.05	0.07	0.09	0.10	0.13	0.18
	S₂							0.08	0.12	0.16	0.18	0.23	0.27
8	S₁	0.08	0.12	0.16	0.20	0.23	0.27
	S₂							0.18	0.26	0.34	0.45	0.49	0.55
9	S₁	0.03	0.12	0.28	0.40	0.54	0.62
	S₂							0.20	0.30	0.45	0.50	0.60	0.75
10	S₁	0.10	0.20	0.34	0.40	0.49	0.55
	S₂							0.35	0.40	0.45	0.57	0.67	0.80
11	S₁	0.05	0.07	0.09	0.15	0.22	0.28
	S₂							0.30	0.35	0.48	0.52	0.61	0.70
12	S₁	0.45	0.50	0.55	0.65	0.75	0.85
	S₂							0.48	0.56	0.62	0.70	0.80	0.88
13	S₁	0.18	0.26	0.34	0.45	0.49	0.55
	S₂							0.08	0.12	0.16	0.18	0.23	0.27

Back to article page

ISSN: 1471-2288

Contact us

General enquiries: journalsubmissions@springernature.com